Abstract
Oral anticoagulation is the therapeutic cornerstone in preventing thromboembolic risk in both atrial fibrillation (AF) and venous thromboembolism (VTE). After decades of the sole therapeutic oral anticoagulation option being warfarin, the introduction of non-vitamin K antagonist oral anticoagulants has heralded a new era. Edoxaban is the latest addition to these available for clinical use. Edoxaban was as effective and safer than warfarin in preventing thromboembolic risk in AF patients. Similarly, edoxaban effectiveness and safety was evident when treating VTE patients to prevent recurrent VTE or VTE-related death. Therefore, edoxaban represents a valuable alternative in treating thromboembolic risk for AF and VTE patients.
Keywords:
anticoagulation; atrial fibrillation; edoxaban; stroke; venous thromboembolism.
MeSH terms
-
Administration, Oral
-
Animals
-
Anticoagulants / administration & dosage*
-
Anticoagulants / adverse effects
-
Antidotes / therapeutic use
-
Atrial Fibrillation / blood
-
Atrial Fibrillation / complications
-
Atrial Fibrillation / diagnosis
-
Atrial Fibrillation / drug therapy*
-
Blood Coagulation / drug effects*
-
Coagulants / therapeutic use
-
Hemorrhage / chemically induced
-
Hemorrhage / drug therapy
-
Humans
-
Pyridines / administration & dosage*
-
Pyridines / adverse effects
-
Recurrence
-
Risk Factors
-
Stroke / blood
-
Stroke / diagnosis
-
Stroke / etiology
-
Stroke / prevention & control*
-
Thiazoles / administration & dosage*
-
Thiazoles / adverse effects
-
Treatment Outcome
-
Venous Thromboembolism / blood
-
Venous Thromboembolism / diagnosis
-
Venous Thromboembolism / drug therapy*
-
Venous Thromboembolism / mortality
Substances
-
Anticoagulants
-
Antidotes
-
Coagulants
-
Pyridines
-
Thiazoles
-
edoxaban